4.25

1.62% -0.07

After Hours: 4.31 0.06 +1.41%

Trisalus Life Sciences Inc (TLSI)

Overview News Price History Discussions Forecast

Trisalus Life Sciences Inc stock is traded at $4.25, with a volume of 234.46K. It is down -1.62% in the last 24 hours and up +4.42% over the past month. TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

Previous Close:

$4.32

Open:

$4.36

24h Volume:

234.46K

Relative Volume:

5.09

Market Cap:

$128.68M

Revenue:

$15.33M

Net Income/Loss:

$-40.19M

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+4.42%

1M Performance:

+4.42%

6M Performance:

-43.78%

1Y Performance:

+5.99%

1-Day Range:

$4.1484

$4.36

1-Week Range:

$4.06

$4.65

52-Week Range:

$3.61

$10.42

Trisalus Life Sciences Inc Stock (TLSI) Company Profile

Name

Trisalus Life Sciences Inc

Sector

Healthcare (1200)

Industry

Medical Devices (153)

Phone

415 336 8917

Address

6272 WEST 91ST AVENUE, WESTMINSTER

Employee

Twitter

Next Earnings Date

Latest SEC Filings

TLSI's Discussions on Twitter

Compare TLSI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TLSI Trisalus Life Sciences Inc	4.25	128.68M	15.33M	-40.19M	0	0.00
ABT Abbott Laboratories	118.95	208.18B	41.22B	5.77B	6.49B	2.94
SYK Stryker Corp	388.14	148.70B	21.97B	3.59B	3.21B	6.74
BSX Boston Scientific Corp	90.75	133.32B	15.91B	1.79B	1.89B	0.82
MDT Medtronic Plc	86.27	111.27B	33.00B	4.29B	5.50B	2.71
EW Edwards Lifesciences Corp	72.07	42.66B	6.60B	4.16B	490.10M	2.34

Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-11-24	Initiated	ROTH MKM	Buy
Oct-25-24	Initiated	Northland Capital	Outperform
Sep-16-24	Initiated	Oppenheimer	Outperform
May-30-24	Initiated	Canaccord Genuity	Buy

Trisalus Life Sciences Inc Stock (TLSI) Latest News

Nov 25, 2024

Trisalus life sciences director Wahlstrom Mats buys $22,750 in stock - Investing.com

Nov 25, 2024

Trisalus life sciences director Wahlstrom Mats buys $22,750 in stock By Investing.com - Investing.com UK

Nov 25, 2024

Nov 23, 2024

TriSalus Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 23, 2024

Trisalus life sciences director Mats Wahlstrom buys $47,056 in stock By Investing.com - Investing.com Australia

Nov 23, 2024

Trisalus life sciences director Mats Wahlstrom buys $47,056 in stock - Investing.com India

Nov 23, 2024

Nov 20, 2024

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of "Buy" from Analysts - MarketBeat

Nov 20, 2024

Nov 19, 2024

Canaccord Genuity Group Lowers TriSalus Life Sciences (NASDAQ:TLSI) Price Target to $11.00 - Defense World

Nov 19, 2024

Nov 15, 2024

Canaccord cuts TriSalus shares target, keeps buy rating on Q3 report - Investing.com Canada

Nov 15, 2024

TriSalus Life Sciences (NASDAQ:TLSI) Given New $11.00 Price Target at Canaccord Genuity Group - MarketBeat

Nov 15, 2024